Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for the Treatment of Headache Disorders: Sub-Study I
NCT03341689Phase 1Completed
- Sponsor
- Yale University
- Start
- Nov 2017
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in migraine (4 arms), sponsored by Yale University. Primary endpoints: Change in migraine headache days, Change in migraine attack frequency and 6 more. Started Nov 2017; status: completed.
02
Drugs
psilocybin
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03341689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341689.